Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance

PURPOSE: A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission. PATIENTS AND METHODS:...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Zhang, Wenyong W., Cortes, Jorge E., Yao, Hui, Zhang, Li, Reddy, Neelima G., Jabbour, Elias, Kantarjian, Hagop M., Jones, Dan
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2009
Fag:
Original Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799062/
https://ncbi.nlm.nih.gov/pubmed/19506164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.4076
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker